Probucol inhibits oxidative modification of low density lipoprotein.
about
Probucol for type 2 diabetes mellitusProbucol for type 2 diabetes mellitusProbucol attenuates the development of aortic atherosclerosis in cholesterol-fed rabbitsAdd-on effect of probucol in atherosclerotic, cholesterol-fed rabbits treated with atorvastatinRational drug design applied to myeloperoxidase inhibition.The role of lipid peroxidation in arteriosclerosis.Cholesteryl ester accumulation in macrophages incubated with low density lipoprotein pretreated with cigarette smoke extractLow density lipoprotein rich in oleic acid is protected against oxidative modification: implications for dietary prevention of atherosclerosisHomocyst(e)ine and heart disease: pathophysiology of extracellular matrix.Why are low-density lipoproteins atherogenic?Atherosclerosis: inhibition of regression as therapeutic possibilitiesEndothelial dysfunction in diabetes: pathogenesis, significance, and treatment.Dissociation of atherogenesis from aortic accumulation of lipid hydro(pero)xides in Watanabe heritable hyperlipidemic rabbits.Abnormally high thromboxane biosynthesis in homozygous homocystinuria. Evidence for platelet involvement and probucol-sensitive mechanismVascular cell adhesion molecule-1 (VCAM-1) gene transcription and expression are regulated through an antioxidant-sensitive mechanism in human vascular endothelial cells.Low-dose alpha-tocopherol improves and high-dose alpha-tocopherol worsens endothelial vasodilator function in cholesterol-fed rabbits.Inhibition by interferon-gamma of human mononuclear cell-mediated low density lipoprotein oxidation. Participation of tryptophan metabolism along the kynurenine pathway.Antioxidant: a new role for RU-486 and related compoundsProteinuria in passive Heymann nephritis is associated with lipid peroxidation and formation of adducts on type IV collagen.Dietary probucol preserves endothelial function in cholesterol-fed rabbits by limiting vascular oxidative stress and superoxide generation.Inhibition of hypercholesterolemia-induced atherosclerosis in the nonhuman primate by probucol. I. Is the extent of atherosclerosis related to resistance of LDL to oxidation?Preservation of the endogenous antioxidants in low density lipoprotein by ascorbate but not probucol during oxidative modificationRenal vasoconstriction caused by short-term cholesterol feeding is corrected by thromboxane antagonist or probucol.Probucol prevents the progression of atherosclerosis in Watanabe heritable hyperlipidemic rabbit, an animal model for familial hypercholesterolemiaAntiatherogenic effect of probucol unrelated to its hypocholesterolemic effect: evidence that antioxidants in vivo can selectively inhibit low density lipoprotein degradation in macrophage-rich fatty streaks and slow the progression of atherosclerosAnti-oxidants-- a protective role in cardiovascular disease?Effect of antioxidants on oxidative modification of LDL.Probucol preserves endothelial function by reduction of the endogenous nitric oxide synthase inhibitor level.Reactive oxygen species in cardiovascular disease.Chance and serendipity in science: two examples from my own career.Experimental and clinical studies show that the probucol derivative AGI-1067 prevents vascular growth.In vivo visualization and attenuation of oxidized lipid accumulation in hypercholesterolemic zebrafish.High preprocedural non-HDL cholesterol is associated with enhanced oxidative stress and monocyte activation after coronary angioplasty: possible implications in restenosisStimulated arachidonate metabolism during foam cell transformation of mouse peritoneal macrophages with oxidized low density lipoprotein.Ischemic acute renal failure and antioxidant therapy in the rat. The relation between glomerular and tubular dysfunction.Lowering cholesterol, 1988. Rationale, mechanisms, and means.Evidence for an additional intracellular site of action of probucol in the prevention of oxidative modification of low density lipoprotein. Use of a new water-soluble probucol derivative.Beta-carotene inhibits atherosclerosis in hypercholesterolemic rabbits.Direct evidence for a protein recognized by a monoclonal antibody against oxidatively modified LDL in atherosclerotic lesions from a Watanabe heritable hyperlipidemic rabbit.Glycation, oxidation, and lipoxidation in the development of the complications of diabetes: a carbonyl stress hypothesis
P2860
Q24195163-79645C4E-EDD2-4203-A72C-ACE8D956297EQ24240606-ACE5979F-B012-40C7-AC3A-5BC40A067E34Q28359752-04A86CDD-B320-4B1A-8740-07CD202A0B42Q28538633-3C986FC4-B06A-4E8D-9948-A2019CEEC219Q30372838-B5D51574-CFE3-4EC6-8E0E-9C60DD286E3BQ30441742-23DEFECE-E8BB-4F03-B34D-CF46071792F0Q33564788-C09741F1-A80D-4E54-B888-135650049E5DQ33592229-CCDA99B5-28AF-427F-A671-FA5635576FF6Q33606377-5DDD63AF-0A1D-4533-8FCE-E61A40D1AE52Q33607440-A12DEB4B-EA50-49E3-82AF-A8D5EACDE2A6Q33611394-CA763187-3016-4BAB-A0DB-0230F9F7CD5DQ33776230-44EB651A-4BE4-4399-9E5F-AAE603A97751Q33855324-1BA3BE8A-5A05-4029-A4B6-C5AE75DCD1B7Q33902343-71518BD1-E8E7-462A-AF12-1F493ED8E371Q33905168-2211E0C1-A9B5-4356-A4AB-FAA070FD215BQ34127841-F827BD6A-CF8C-4E44-B2F5-FE687844612BQ34145731-048FE12D-8EA0-4A43-BD78-9C0EABADF21DQ34157921-F918BCFE-85AC-4184-B6AD-6194652CC174Q34190557-FCA9A43A-8684-4F2D-88F6-5770DA4691F2Q34223247-746AAF58-F540-443D-A75E-1EAA361DA505Q34234638-75979E0B-F71D-4AD4-A280-281345735A31Q34237254-4172D653-A09E-4E18-9038-03DA5AE14ECAQ34263908-1A19B3D2-7852-45DF-9CBA-CCF483BC5AD5Q34340579-E68C0B9E-A18C-49C0-9831-36C42875EB4BQ34360883-1F1E88FE-D877-4C9C-B9A6-F2F620BB752FQ34515450-4D3B6655-4694-4BB3-8DD3-F47E4863901BQ34636198-5800EBA9-9699-4980-B0B2-6DADD970D050Q35044177-03D7F054-1F1C-4C0D-8EC8-5E2B8BD8E371Q35165194-A26E7D31-AFDA-435F-818E-FDE0368B6C83Q35516016-1EA10EE3-477C-4DBF-B33B-D98B0A651B6EQ35570967-3F9F3B4B-B1AB-46D9-A5BC-7BBABC891ACDQ35578606-978D5812-64E5-440C-8FAE-BDEAC1176930Q35581270-F89EBF9A-A99A-4D99-8C83-581BECB6808BQ35586059-AD798F57-6724-4D1E-B9F9-6CBC2CBE4670Q35588716-62051B9B-4E03-4861-A7BE-74CCC360A972Q35588973-C72CB1DD-BA8C-4EB9-BD06-2C361A253B9CQ35602530-7D8C7EBD-EC06-473C-A137-BE2E05CC2F8FQ35765213-BEAF24CD-7C33-45CB-BB44-97E36BD107B2Q35817369-3877AE2F-F0B7-418B-8939-A3AA426E03D9Q36052417-B4805E4F-5452-43EA-AEC7-3FFF73544009
P2860
Probucol inhibits oxidative modification of low density lipoprotein.
description
1986 nî lūn-bûn
@nan
1986 թուականի Փետրուարին հրատարակուած գիտական յօդուած
@hyw
1986 թվականի փետրվարին հրատարակված գիտական հոդված
@hy
1986年の論文
@ja
1986年論文
@yue
1986年論文
@zh-hant
1986年論文
@zh-hk
1986年論文
@zh-mo
1986年論文
@zh-tw
1986年论文
@wuu
name
Probucol inhibits oxidative modification of low density lipoprotein.
@ast
Probucol inhibits oxidative modification of low density lipoprotein.
@en
Probucol inhibits oxidative modification of low density lipoprotein.
@nl
type
label
Probucol inhibits oxidative modification of low density lipoprotein.
@ast
Probucol inhibits oxidative modification of low density lipoprotein.
@en
Probucol inhibits oxidative modification of low density lipoprotein.
@nl
prefLabel
Probucol inhibits oxidative modification of low density lipoprotein.
@ast
Probucol inhibits oxidative modification of low density lipoprotein.
@en
Probucol inhibits oxidative modification of low density lipoprotein.
@nl
P2093
P2860
P356
P1476
Probucol inhibits oxidative modification of low density lipoprotein.
@en
P2093
D Steinberg
J L Witztum
R C Pittman
S Parthasarathy
P2860
P304
P356
10.1172/JCI112349
P407
P577
1986-02-01T00:00:00Z